| Literature DB >> 24061064 |
Latania K Logan1, Sara A Healy, William J Kabat, Guorong Liu, Christine L Sullivan, Alan M Peaceman, Tina Q Tan.
Abstract
Entities:
Keywords: Staphylococcus aureus; epidemiology; infections in obs and gyn; molecular epidemiology; pregnancy
Mesh:
Year: 2013 PMID: 24061064 PMCID: PMC3906301 DOI: 10.4161/viru.26435
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882
Table 1. Demographics characteristics of 102 pregnant women
| Characteristic | Women with | Patients without | |
|---|---|---|---|
| Nasal colonization* | 17 | NA | NA |
| Vaginal colonization | 7 | NA | NA |
| Age, mean years (SD) | 32.26 (5.01) | 32.94 (6.35) | 0.74 |
| # of maternal medical problems (SD) | 3.50 (3.59) | 3.58 (3.29) | 0.98 |
| White/Caucasian/Other | 17 (74) | 65 (82) | |
| Black/African-American | 3 (13) | 4 (5) | |
| Hispanic/Latino | 3 (13) | 10 (13) | |
| Single | 7 (30) | 20 (25) | |
| Married | 16 (70) | 59 (75) | |
| Public Insurance | 3 (13) | 13 (16) | 0.99 |
| Multigravida | 16 (70) | 49 (64) | 0.8 |
| Multiparity | 13 (57) | 31 (39) | 0.16 |
| GBS positive | 3 (13) | 12 (15) | 0.83 |
| C-section | 4 (17) | 32 (41) | 0.04 |
| Antibiotics at delivery† | 7 (30) | 39 (49) | 0.11 |
| Gestational age, weeks (SD) | 38.97 (1.28) | 38.58 (1.58) | 0.21 |
| Infant length of stay, days (range) | 2.90 (1–7) | 2.26 (1–6) | 0.07 |
One woman was colonized both nasal and vaginally; †prophylactic or therapeutic.

Figure 1. Relationship analysis of Staphylococcus aureus isolates
Table 2. Characteristics of Staphylococcus aureus in a cohort of pregnant women
| Isolate | Location | Toxin/virulence gene profile | Kirby Bauer disc assays | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MecA | PVL | Cap5 | ACME ArcA | Chrome ArcA | SasX | OX | TMP/SMX | CC | ERY | LVX | LZD | RIF | Van | ||
| 1 | N | Neg | Neg | Neg | Neg | Neg | Neg | S | S | S | S | R | S | S | S |
| 2 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 3 | N | Neg | Neg | Neg | Neg | Pos | Neg | S | S | S | R | S | S | S | S |
| 4 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 5 | N | Neg | Pos | Neg | Neg | Neg | Neg | S | S | S | S | S | S | S | S |
| 6 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 7 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | R | S | S | S | S |
| 8 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 9 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 10 | N | Neg | Neg | Neg | Neg | Pos | Neg | S | S | S | R | S | S | S | S |
| 11 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 12 | N | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 13 | V | Neg | Neg | Neg | Pos | Pos | Neg | S | S | S | S | S | S | S | S |
| 14 | V | Neg | Pos | Neg | Neg | Neg | Neg | S | S | S | S | S | S | S | S |
| 15 | V | Neg | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
| 16 | V | Neg | Neg | Neg | Neg | Neg | Neg | S | S | S | R | S | S | S | S |
| 17 | V | Pos | Pos | Neg | Neg | Pos | Neg | S | S | S | S | S | S | S | S |
N, nasal; V, vaginal; Pos, positive; Neg, negative; PVL, Panton–Valentine leukocidin; ACME, arginine catabolic mobile element; Ox, oxacillin; TMP/SMX, trimethoprim/sulfamethoxazole; CC, clindamycin; Ery, erythromycin; LVX, levofloxacin; LZD, linezolid; RIF, rifampin; Van, vancomycin